AR045144A1 - Metodo para tratar a un paciente que tiene un neoplasma o que tiene riesgo de desarrollarlo - Google Patents

Metodo para tratar a un paciente que tiene un neoplasma o que tiene riesgo de desarrollarlo

Info

Publication number
AR045144A1
AR045144A1 ARP040102684A ARP040102684A AR045144A1 AR 045144 A1 AR045144 A1 AR 045144A1 AR P040102684 A ARP040102684 A AR P040102684A AR P040102684 A ARP040102684 A AR P040102684A AR 045144 A1 AR045144 A1 AR 045144A1
Authority
AR
Argentina
Prior art keywords
patient
neoplasm
treat
developing
risk
Prior art date
Application number
ARP040102684A
Other languages
English (en)
Original Assignee
Combinatorx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Combinatorx Inc filed Critical Combinatorx Inc
Publication of AR045144A1 publication Critical patent/AR045144A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Método para tratar a un paciente que tiene cáncer u otro neoplasma por administración al paciente de una combinación de pentamidina o un análogo de pentamidina y un agente antiproliferativo como por ejemplo vimblastina, carboplatino, etopósido, gemcitabina, doxorrubicina, entre otros de manera simultánea o a intervalos de 14, 10, 5 días o 24 horas entre sí en cantidades suficientes para tratar al paciente. Composición que contiene dicha combinación.
ARP040102684A 2003-07-28 2004-07-28 Metodo para tratar a un paciente que tiene un neoplasma o que tiene riesgo de desarrollarlo AR045144A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US49075903P 2003-07-28 2003-07-28

Publications (1)

Publication Number Publication Date
AR045144A1 true AR045144A1 (es) 2005-10-19

Family

ID=34115433

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040102684A AR045144A1 (es) 2003-07-28 2004-07-28 Metodo para tratar a un paciente que tiene un neoplasma o que tiene riesgo de desarrollarlo

Country Status (10)

Country Link
US (1) US20050054708A1 (es)
EP (1) EP1651211A4 (es)
JP (1) JP2007500698A (es)
KR (1) KR20060052820A (es)
CN (1) CN1829509A (es)
AR (1) AR045144A1 (es)
AU (1) AU2004261148A1 (es)
CA (1) CA2529521A1 (es)
TW (1) TW200522947A (es)
WO (1) WO2005011572A2 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6569853B1 (en) * 2000-11-06 2003-05-27 Combinatorx, Incorporated Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders
AR047938A1 (es) * 2003-08-25 2006-03-15 Combinatorx Inc Formulaciones, conjugados y combinaciones de farmacos para el tratamiento de neoplasmas
JP2007505914A (ja) * 2003-09-18 2007-03-15 コンビナトアールエックス インコーポレーティッド 新生物の治療のための薬物の併用方法
US20050158320A1 (en) * 2003-11-12 2005-07-21 Nichols M. J. Combinations for the treatment of proliferative diseases
US20050100508A1 (en) * 2003-11-12 2005-05-12 Nichols M. J. Methods for identifying drug combinations for the treatment of proliferative diseases
JP2007513888A (ja) * 2003-11-24 2007-05-31 ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 縮合環ジカチオン性抗原虫剤及びそれらのプロドラッグ
KR101226631B1 (ko) 2004-02-06 2013-01-28 쓰레솔드 파마슈티컬스, 인코포레이티드 항암 치료 방법
EP1996211A4 (en) * 2006-03-09 2010-03-17 Lawrence Richard Bernstein GALLIUM COMPOSITIONS FOR THE TREATMENT OF LIVER CANCER AND METHODS OF USE
EP2034981A1 (en) * 2006-03-27 2009-03-18 The Government of the United States of America as Represented by The Department of Health and Human Services Diamidine inhibitors of tdp1
WO2008124691A1 (en) * 2007-04-05 2008-10-16 Threshold Pharmaceuticals, Inc. Glufosfamide combination therapy
CN101138558B (zh) * 2007-09-13 2010-08-25 汕头大学医学院 喷他脒及死亡结构域受体配体联合应用
WO2010019396A1 (en) * 2008-08-13 2010-02-18 Threshold Pharmaceuticals, Inc. Administration of glufosfamide for the treatment of cancer
US20120128667A1 (en) * 2009-05-01 2012-05-24 Oncozyme Pharma Inc. Pentamidine combinations for treating cancer
AU2013362755B2 (en) 2012-12-21 2018-09-13 Verlyx Pharma Inc. Uses and methods for the treatment of liver diseases or conditions
WO2016014674A1 (en) * 2014-07-22 2016-01-28 University Of Maryland, College Park Linked diaryl compounds with anticancer properties and methods of using the same
KR102460579B1 (ko) * 2020-06-26 2022-10-31 선문대학교 산학협력단 푸라미딘 및 hbc를 포함하는 뇌암 치료, 개선 또는 예방용 조성물
CN114853679A (zh) * 2021-02-04 2022-08-05 清药同创(北京)药物研发中心有限公司 一种苯并咪唑类enl蛋白抑制剂及其制备方法和用途
US20250382261A1 (en) * 2021-11-05 2025-12-18 The Broad Institute, Inc. Pentamidine analogs

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5428051A (en) * 1992-10-13 1995-06-27 University Of North Carolina Methods of combating pneumocystis carinii pneumonia and compounds useful therefor
US5443962A (en) * 1993-06-04 1995-08-22 Mitotix, Inc. Methods of identifying inhibitors of cdc25 phosphatase
US5521189A (en) * 1994-05-06 1996-05-28 The University Of Nc At Ch Methods of treating pneumocystis carinii pneumonia
US5602172A (en) * 1994-05-06 1997-02-11 The University Of North Carolina At Chapel Hill Methods of inhibiting Pneumocystis carinii pneumonia, Giardia lamblia, and Cryptosporidium and compounds useful therefor
US5770585A (en) * 1995-05-08 1998-06-23 Kaufman; Robert J. Homogeneous water-in-perfluorochemical stable liquid dispersion for administration of a drug to the lung of an animal
US5643935A (en) * 1995-06-07 1997-07-01 The University Of North Carolina At Chapel Hill Method of combatting infectious diseases using dicationic bis-benzimidazoles
US5723495A (en) * 1995-11-16 1998-03-03 The University Of North Carolina At Chapel Hill Benzamidoxime prodrugs as antipneumocystic agents
AU3511197A (en) * 1996-07-03 1998-01-21 Prm Pharmaceuticals, Inc. Berberine alkaloids as a treatment for chronic, protozoally-induced diarrhea
US6008247A (en) * 1998-02-27 1999-12-28 The University Of North Carolina At Chapel Hill 2,4-bis[(4-amidino)phenyl]furans as anti-Pneumocystis carinii agents
DE69907476T2 (de) * 1998-08-20 2004-04-15 The University Of North Carolina At Chapel Hill Office Of Technology Development Dibenzothiophene derivate und ihre verwendung
DE69933890T2 (de) * 1998-09-17 2007-03-15 University Of North Carolina At Chapel Hill Antimykotische wirkung von dikationischen molekülen
DK1231910T3 (da) * 1999-11-16 2009-08-31 Oncozyme Pharma Inc Pentamidin til behandling af cancer
US6777433B2 (en) * 1999-12-22 2004-08-17 Merck Frosst Canada & Co. Protein tyrosine phosphatase 1B (PTP-1B) inhibitors containing two ortho-substituted aromatic phosphonates
US6911468B2 (en) * 2000-05-22 2005-06-28 Takeda Chemical Industries, Ltd. Tyrosine phosphatase inhibitors
US6569853B1 (en) * 2000-11-06 2003-05-27 Combinatorx, Incorporated Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders
US6642221B1 (en) * 2000-11-15 2003-11-04 Parker Hughes Institute Vanadium compounds as anti-proliferative agents
US6693125B2 (en) * 2001-01-24 2004-02-17 Combinatorx Incorporated Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders
WO2002069949A2 (en) * 2001-03-06 2002-09-12 Prendergast Patrick T Combination therapy for reduction of toxycity of chemotherapeutic agents
US20030161893A1 (en) * 2001-09-07 2003-08-28 Taolin Yi PTPase inhibitors and methods of using the same
EP1545544A2 (en) * 2002-07-11 2005-06-29 Combinatorx, Incorporated Combinations of drugs for the treatment of neoplasms
AU2003251904A1 (en) * 2002-07-15 2004-02-02 Combinatorx, Incorporated Combinations of drugs for the treatment of neoplasms

Also Published As

Publication number Publication date
WO2005011572A2 (en) 2005-02-10
WO2005011572A3 (en) 2005-03-10
TW200522947A (en) 2005-07-16
KR20060052820A (ko) 2006-05-19
CN1829509A (zh) 2006-09-06
EP1651211A4 (en) 2006-11-22
AU2004261148A1 (en) 2005-02-10
JP2007500698A (ja) 2007-01-18
CA2529521A1 (en) 2005-02-10
US20050054708A1 (en) 2005-03-10
EP1651211A2 (en) 2006-05-03

Similar Documents

Publication Publication Date Title
AR045144A1 (es) Metodo para tratar a un paciente que tiene un neoplasma o que tiene riesgo de desarrollarlo
BR9502707A (pt) Composto composição farmacêutica e método para o tratamento de uma afecção
AR047841A1 (es) Metodos y composiciones para el tratamiento de transtornos inmunoinflamatorios
UY28213A1 (es) Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
AR051446A1 (es) Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
AR034746A1 (es) Combinaciones para el tratamiento de trastornos inflamatorios
AR109605A2 (es) Método para tratar enfermedades vasculares periféricas, composición y utilización
NO20061325L (no) Kombinasjon av legemidler for behandling av neoplasmer
FR2869231B1 (fr) Composition therapeutique contenant au moins un derive de la pyrrolobenzodiazepine et la fludarabine
AR054233A1 (es) Composiciones de anticuerpos igg2
BRPI0407375A (pt) Métodos para tratar dor por meio da administração de um antagonista do fator de crescimento neural e u nsaid e composições contendo os mesmos
BR0308206A (pt) Composição oral sinergìstica com composto volátil de enxofre para o controle de odor para hálito, e, método para neutralizar sinergisticamente o odor de hálito de composto volátil de enxofre
CU23794B7 (es) Inhibidores macrocíclicos de la replicación del virus de la hepatitis c
BR112021021921A2 (pt) Agente, uso de um agente e método de tratamento ou prevenção de uma doença metabólica
ES2154287T3 (es) Procedimiento para modificar el crecimiento de los pelos y/o de los cabellos y composiciones utilizables a este efecto.
CO2021004141A2 (es) Moduladores de la expresión de pnpla3
AR105712A1 (es) Composiciones de insulina de rápida acción
BRPI0410503B8 (pt) composição tópica e uso da composição
PT1143955E (pt) Combinacao de inibidores de fbpase e sensibilizadores de insulina para o tratamento de diabete
BR0312597A (pt) Combinações de drogas para o tratamento de neoplasmas
DE60136826D1 (de) Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs
SE0300971D0 (sv) Nitric oxide in treatment of inflammation
CL2021001096A1 (es) Métodos para tratar el síndrome mielodisplásico. (divisional de la solicitud no. 202000196)
BR0315314A (pt) Método para o tratamento ou prevenção de sintomas de vasomotores em um paciente com necessidade do mesmo
ES2152272T3 (es) Uso de sulodexide y de medicamentos que lo contienen para el tratamiento de la nefropatia diabetica.

Legal Events

Date Code Title Description
FB Suspension of granting procedure